Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease  

作　　者：Toshifumi Yodoshi 

机构地区：[1]Division of Gastroenterology,Hepatology and Nutrition,The Hospital for Sick Children,Toronto M5G 1X8,Ontario,Canada

出　　处：《World Journal of Gastroenterology》2024年第47期5070-5075,共6页世界胃肠病学杂志（英文）

摘　　要：In this article,we comment on the article by Qu and Li,focusing specifically on the non-invasive diagnostic approaches for metabolic dysfunction-associated steatotic liver disease(MASLD).MASLD is the most common chronic liver disease in children.Nearly half of pediatric MASLD cases progress to metabolic dysfunction-associated steatohepatitis at diagnosis,often with comorbidities like renal disease,hypertension,type 2 diabetes,and mental health disorders.Early diagnosis and continuous intervention are crucial for managing this“silent organ”disease.Screening is recommended for children aged nine and older with obesity.Liver biopsy remains the diagnostic gold standard;however,due to its invasiveness,non-invasive methods-biomarkers,anthropometric algorithms,serum tests,and imaging-are increasingly vital.This editorial provides an overview of the current non-invasive diagnostic approaches for pediatric MASLD or liver fibrosis.

关 键 词：Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis Insulin resistance Oxidative stress 

分 类 号：R563.1[医药卫生—呼吸系统] R575.5[医药卫生—内科学]